MicroPulse TLT - UK Study

Launched by IMPERIAL COLLEGE HEALTHCARE NHS TRUST · Oct 20, 2022

Keywords

ClinConnect Summary

The MicroPulse TLT - UK Study is a clinical trial designed to evaluate a new treatment called MicroPulse Transscleral Laser Therapy (MPTLT) for patients suffering from various types of glaucoma, a condition that affects the eyes and can lead to vision loss. This study aims to determine how effective MPTLT is in lowering eye pressure and improving the quality of life for those who may be struggling with medications or considering surgery.

To participate in this trial, individuals must be at least 18 years old and have been diagnosed with glaucoma or high eye pressure that requires treatment. They should also be in a situation where traditional surgery is too risky. Participants will need to be willing to follow the study's guidelines, attend follow-up appointments, and consent to have their health information securely stored. The trial is not yet recruiting, so interested individuals will need to wait for further announcements. Overall, this study could provide important insights into a new treatment option for managing glaucoma effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with glaucoma or ocular hypertension deemed clinically suitable for MPTLT treatment by their treating ophthalmologist; this includes but is not limited to (a) need for lower IOP, (b) need for fewer medications based on side effects, poor compliance, adverse effect on lifestyle or (c) evidence of disease progression based on function or structure
• • Risk of invasive surgical procedure deemed too high by patient or surgeon
• • Aged 18 years or older
• • The ability to understand and comply with the trial consent process and procedures
• • Willingness to be part of a national registry
• • Ability to attend for follow-up
• • Ability to give informed consent, or consent given by relative or carer
• Exclusion Criteria:
• • Clinical situations where in the opinion of the investigator, the ocular surface may be compromised by probe contact, including severe ocular surface inflammation
• • Inability to give informed consent
• • Unwillingness to have clinical data stored in a secure electronic format
• • Inability to comply with the study or follow-up procedures